The world of clinical trials is undergoing an evolution as the rise of decentralized clinical trials (DCTs) brings about a change in the way researchers conduct studies. With innovative technologies and novel approaches to trial management, a new breed of trailblazers is paving the way for the future of clinical research. In this blog article, we’ll explore several companies making waves in the decentralized clinical trials landscape, showcasing the progress they have made in recent years. From blockchain-powered data management to AI-driven patient recruitment, these organizations are breaking down traditional barriers and empowering patients to participate in trials with greater ease, flexibility, and convenience.
The space is dominated by large contract research players, like IQVIA, In this post, we will focus on relatively young companies enabling decentralized clinical trials.
Deep 6 AI
Deep 6 AI is a health technology company founded in 2015, specializing in artificial intelligence (AI) solutions for decentralized clinical trials. Their platform focuses on patient recruitment, trial feasibility, and site selection by analyzing structured and unstructured real-world data from electronic health records (EHRs) and other sources.
Using natural language processing (NLP) and machine learning algorithms, Deep 6 AI’s platform identifies eligible patients for clinical trials based on specific criteria such as demographics, medical history, and diagnoses. This helps researchers expedite the recruitment process, which is often a time-consuming and costly aspect of clinical trials.
The platform also assists in determining trial feasibility by providing insights into patient populations, ensuring trials are designed with realistic expectations. Additionally, Deep 6 AI’s solution aids in selecting the most suitable trial sites, factoring in aspects like patient availability, site performance, and investigator experience.
ClinTex is a health technology company founded in 2017 that utilizes blockchain and machine learning to enhance the efficiency and cost-effectiveness of decentralized clinical trials. Their primary product, Clinical Trials Intelligence (CTi), is a suite of seven applications aimed at addressing various clinical trial pain points.
By leveraging blockchain technology, ClinTex ensures data integrity, security, and transparency, which are crucial in clinical trial processes. CTi’s machine learning algorithms identify trends, predict outcomes, and optimize trial performance by analyzing data from various sources, enabling proactive issue resolution.
CTi offers a range of applications, including operational analytics, predictive recruitment, and risk-based monitoring, to streamline trial management, reduce patient attrition, and improve trial performance. Its real-time monitoring capabilities allow for better collaboration and informed decision-making among stakeholders.
In summary, ClinTex is aiming to improve decentralized clinical trials with its blockchain-based Clinical Trials Intelligence platform. By utilizing machine learning and blockchain technology, ClinTex aims to improve trial efficiency, reduce costs, and accelerate the development of new medical treatments.
Aural Analytics is a health technology company founded in 2015 that focuses on developing speech analytics as a digital biomarker for use in decentralized clinical trials. Their platform is designed to monitor and assess neurological, respiratory, and mental health conditions by analyzing patients’ speech patterns.
The technology behind Aural Analytics is built on advanced algorithms and machine learning techniques that extract clinically relevant information from speech data. This includes aspects like pronunciation, fluency, and rhythm, which can provide insights into a patient’s health status and disease progression.
One of the key advantages of Aural Analytics’ platform is its ability to support multiple languages and work across various devices, making it adaptable and inclusive for clinical trials conducted in different countries and populations.In decentralized clinical trials, the platform enables remote patient monitoring, reducing the need for in-person assessments. This not only improves patient convenience but also helps in increasing trial participation and retention rates. Additionally, it allows researchers to collect data continuously, providing real-time insights into treatment efficacy and safety.
On March 29, 2023, Aural’s Speech Vitals – ALS technology received Breakthrough Device Designation from the FDA. The software assists in monitoring ALS in adults by collecting and analyzing speech recordings, aiming to provide more effective disease management. Aural Analytics plans to pursue further applications for Speech Vitals post-regulatory clearance.
Teckro is a clinical trial technology company founded in 2015 in Ireland. Their digital platform aims to simplify and modernize clinical trial conduct by streamlining trial management and providing mobile access to essential information. Teckro’s solution enhances efficiency, communication, and collaboration among sponsors, CROs, trial sites, investigators, and patients. Teckro has accumulated $66M in funding through four rounds, with the latest round occurring on November 24, 2021.
Key features include mobile access to trial information, real-time updates and notifications, secure communication, machine learning and AI for optimized search and retrieval of trial data, and integration with existing systems. With Teckro’s mobile app, investigators and clinical trial staff can quickly access study protocols, inclusion and exclusion criteria, and other critical trial details. The platform’s real-time updates help maintain consistency across trial sites and improve overall trial conduct. By leveraging machine learning and artificial intelligence, Teckro ensures efficient decision-making and improved patient care.
myClin is a Philadelphia-based company that offers a secure, collaborative platform for clinical trial management. Founded in 2008, myClin focuses on streamlining communication, document management, and compliance tracking among clinical research stakeholders, including sponsors, contract research organizations (CROs), clinical trial sites, and investigators.
myClin’s platform addresses some of the key challenges in clinical trial management, such as information silos, fragmented communication, and inefficient document handling. By providing a centralized, user-friendly system, myClin makes it easier for clinical trial teams to work together and ensure that essential trial information is easily accessible and up-to-date.
Andaman7 is a Belgium-based health technology company founded in 2015. The company’s primary focus is on creating a patient-centered platform for decentralized clinical trials, as well as for the management of personal health records. Their vision is to improve the overall healthcare ecosystem by facilitating collaboration between patients, researchers, and healthcare professionals while ensuring patient privacy and data security. Andaman7 has garnered $2.6M in total funding across three rounds, with the most recent round taking place on October 1, 2017.
Andaman7’s solution is a mobile application called A7 Health, which serves as a personal health record (PHR) for patients and a remote data collection tool for researchers. The app empowers patients by allowing them to collect, store, and manage their health data securely on their smartphones. Additionally, the platform enables patients to share their data with healthcare providers, researchers, and other authorized parties on a need-to-know basis, maintaining control over their information.
Reify Health is a healthcare technology company that focuses on accelerating clinical trials and improving the overall clinical research process. Founded in 2013 and headquartered in Boston, Massachusetts, Reify Health provides a cloud-based platform designed to streamline clinical trial management for sponsors, clinical research organizations (CROs), and clinical trial sites.
Reify Health’s primary product is StudyTeam, a platform that offers an array of tools and features for clinical trial management, and it can be integrated with EHRs.
Science 37’s platform leverages mobile technology and AI to enable patients to participate in clinical trials from their homes. This reduces patient burden and improves the diversity and inclusiveness of trials. The company uses AI for analytics and patient recruitment. The company was founded in 2014, and since then it has accumulated $347.5M funding with the latest round happening inOctober 2021.
In April 2023 Science 37 announced a multi-year partnership with Amazon Web Services (AWS) to expand and speed up the adoption of the Science 37 Metasite, a platform for decentralized clinical trials. Science 37 will use AWS’s security, analytics, and machine learning services to improve decision-making, patient safety, and trial length. This collaboration aims to increase trial enrollment, patient retention, and patient diversity while accelerating the regulatory submission process. Earlier this year Science 37 acquired the life sciences platform from Vault Health to enhance the clinical trial workflow orchestration and data interoperability of its platform.
Medable provides a decentralized trial platform to reduce the time of clinical trial processes. They use digital and AI tools to speed up patient recruitment and improve patient engagement. The platform also supports remote data collection and real-time data analysis. In 2020, Medable secured $91 million in Series C funding led by Sapphire Ventures.
On June 20, 2023, Medable Inc. and the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center) announced a collaboration to introduce a toolkit for standardizing the ethics review of decentralized clinical trials (DCTs). Aimed at enhancing the efficiency of patient-centric research, the toolkit offers a uniform framework and best practices for Institutional Review Boards/Ethics Committees (IRBs/ECs). The collaboration intends to address common challenges faced by ethics reviews of DCTs and is expected to streamline the review process and expedite the implementation of DCTs.
THREAD offers a platform for decentralized clinical trials and uses machine learning for predictive modeling and trial data analysis. This company is a pioneer in the use of remote patient research and has launched over 100 virtual trials across various therapeutic areas since it was founded. In May 2023, THREAD expanded its relationship with Amazon Web Services (AWS) to list its services in AWS Marketplace. The collaboration aims to simplify the procurement process for life sciences organizations and provide cost-effective access to THREAD’s research capabilities. AWS customers can now maximize existing discounts to support decentralized research and eCOA technology solutions via THREAD.
Topics: Industry Trends